Unique ID issued by UMIN | UMIN000020150 |
---|---|
Receipt number | R000023272 |
Scientific Title | Imaging study of using positron emission tomography for the effect of nootropics (atomoxetine, sertraline, paroxetine, benztropine) on the athletic performance |
Date of disclosure of the study information | 2015/12/11 |
Last modified on | 2020/12/14 08:58:52 |
Imaging study of using positron emission tomography for the effect of nootropics (atomoxetine, sertraline, paroxetine, benztropine) on the athletic performance
PET imaging for the effect of atomoxetine, sertraline, paroxetine, and benztropine
Imaging study of using positron emission tomography for the effect of nootropics (atomoxetine, sertraline, paroxetine, benztropine) on the athletic performance
PET imaging for the effect of atomoxetine, sertraline, paroxetine, and benztropine
Japan |
healthy adults
Adult |
Others
NO
To investigate the effect of nootropics on the monoaminergic neuron system (dopamine transporter) using positron emission tomography. To evaluate the association between imaging data and blood and/or urine concentration.
PK,PD
Exploratory
The effect of the nootropics on the monoaminergic neuron system (dopamine transporter).
blood and/or urine concentration, MRI
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
4
Prevention
Medicine |
PET, MRI, blood concentration, urine concentration
PET, MRI, blood concentration, urine concentration
PET, MRI, blood concentration, urine concentration
PET, MRI, blood concentration, urine concentration
20 | years-old | <= |
40 | years-old | > |
Male
Subjects who have the ability to provide informed consent and adhere to the protocol.
Subjects without the history of smoking.
Exclusion criteria:
- with past or current history of psychiatric illness
- with past or current history of serious medical illness and/or brain organic diseases
- subject who is contraindicated for the use of MRI
- with past or current history ofsevere liver disease, kidney disease, heart disease, allergy, or severe drug allergy
- subject who are judged as not suitable for participation in this study
20
1st name | Yoshiro |
Middle name | |
Last name | Okubo |
Nippon Medical School
Department of Neuropsychiatry
113-8602
1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan
+81-3-3822-2131
okubo-y@nms.ac.jp
1st name | Amane |
Middle name | |
Last name | Tateno |
Nippon Medical School
Department of Neuropsychiatry
113-8602
1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan
+81-3-3822-2131
amtatneo@nms.ac.jp
Nippon Medical School
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Nippon Medical School Hospital Institutional Review Board
1-1-5, Sendagi, Bunkyo-Ku, Tokyo, Japan
03-3822-2131
clinicaltrial@nms.ac.jp
NO
2015 | Year | 12 | Month | 11 | Day |
https://upload.umin.ac.jp/cgi-bin/icdr/ctr_up_reg_f5.cgi
Partially published
https://upload.umin.ac.jp/cgi-bin/icdr/ctr_up_reg_f5.cgi
20
average dopamine transporter occupancy
caudate putamen
sertraline 25mg 4.8% 6.5%
paroxetine 10mg 3.5% 2.9%
atomoxetine 40mg 1.3% 1.1%
benztropine 0.5mg -4.7% -6.4%
2020 | Year | 12 | Month | 14 | Day |
healthy subjects
1. apply
2. eligibility evaluation, informed consent
3. participation in examination
4. check for adverse events
none
occupancy of dopamine transporter
drug blood concentration
drug urinary concentration
Completed
2015 | Year | 11 | Month | 27 | Day |
2015 | Year | 10 | Month | 07 | Day |
2015 | Year | 12 | Month | 17 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 04 | Month | 30 | Day |
2018 | Year | 05 | Month | 31 | Day |
2018 | Year | 12 | Month | 31 | Day |
2015 | Year | 12 | Month | 10 | Day |
2020 | Year | 12 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023272